ArticleAlpha psychiatry2026
Temporal Interference Stimulation Targeting the Right Amygdala in Adolescents With Depression: A Pilot Feasibility Study.
Article in Alpha psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06452849 (Temporal Interference Stimulation of Amygdala and dLPFC), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Temporal Interference Stimulation of Amygdala and dLPFC: A Randomized Controlled Trial for Adolescent Depression
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adolescent depression necessitates the development of novel therapeutic approaches. Temporal interference stimulation (TIS) is a promising noninvasive neuromodulation technique capable of modulating deep-brain circuits; however, its feasibility in adolescent populations has not yet been established. This open-label pilot study evaluated the feasibility, safety, and tolerability of a five-day TIS protocol targeting the right amygdala in adolescents with depression. Clinical outcomes and neuroimaging findings were assessed as exploratory, hypothesis-generating objectives. Methods: Twelve adolescents with depression received five consecutive daily sessions of TIS (2000 Hz carrier frequency with a 100 Hz difference frequency; 20 min/day) targeting the right amygdala. Feasibility was evaluated on the basis of tolerability and adherence rates. Clinical outcomes were assessed using the 17-item Hamilton Depression Rating Scale (HAMD-17), Montgomery-Åsberg Depression Rating Scale (MADRS), 14-item Hamilton Anxiety Rating Scale (HAMA-14), and the THINC-integrated tool (THINC-it) at baseline, post-treatment, and at one-week and four-week follow-up assessments. Exploratory resting-state functional magnetic resonance imaging (fMRI) was performed to investigate neuromodulatory effects. Results: Nine participants completed the study, corresponding to a completion rate of 75%, with a tolerability rate of 100%. No device-related adverse events were reported. Trends toward improvement were observed in depressive symptoms, anxiety symptoms, and subjective cognitive functioning. From baseline to post-treatment, HAMD-17 and HAMA-14 scores decreased by 52.0% and 56.7%, respectively, and these improvements were maintained at the four-week follow-up, with a 53.3% reduction in depression severity. Exploratory fMRI analyses demonstrated acute increases in functional connectivity between the right amygdala and sensorimotor cortical regions during the first stimulation session. Conclusions: A five-day course of right amygdala-targeted TIS was feasible, safe, and well tolerated in adolescents with depression. The observed improvements in depressive and anxiety symptoms, together with acute alterations in amygdala-cortical functional connectivity, provide hypothesis-generating signals that warrant further investigation in rigorously designed sham-controlled trials. However, given the open-label and uncontrolled nature of the study, these improvements cannot be causally attributed to the intervention. Clinical Trial Registration: The study has been registered on https://clinicaltrials.gov/ (registration number: No: NCT06452849; registration link: https://clinicaltrials.gov/study/NCT06452849).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.